These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1531310)

  • 1. Chemotherapy in advanced ovarian cancer.
    Izard M
    BMJ; 1992 Jan; 304(6819):119. PubMed ID: 1531310
    [No Abstract]   [Full Text] [Related]  

  • 2. Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.
    Williams CJ; Stewart L; Parmar M; Guthrie D
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):120-8. PubMed ID: 1411623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
    BMJ; 1991 Oct; 303(6807):884-93. PubMed ID: 1834291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.
    van Zyl B; Tang D; Bowden NA
    Endocr Relat Cancer; 2018 May; 25(5):R303-R318. PubMed ID: 29487129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum or nonplatinum in recurrent ovarian cancer: that is the question.
    Poveda A; Marth C
    Future Oncol; 2017 Oct; 13(23s):11-16. PubMed ID: 29020823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis.
    Beesley VL; Green AC; Wyld DK; O'Rourke P; Wockner LF; deFazio A; Butow PN; Price MA; Horwood KR; Clavarino AM; Australian Ovarian Cancer Study Group ; Australian Ovarian Cancer Study-Quality Of Life Study Investigators ; Webb PM
    Gynecol Oncol; 2014 Jan; 132(1):130-6. PubMed ID: 24125750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.
    Markman M; Hoskins W
    J Clin Oncol; 1992 Apr; 10(4):513-4. PubMed ID: 1548513
    [No Abstract]   [Full Text] [Related]  

  • 8. Total platinum dose versus platinum dose intensification in ovarian cancer treatment.
    Alberts DS; Garcia DJ
    Semin Oncol; 1994 Apr; 21(2 Suppl 2):11-5; quiz 16, 58. PubMed ID: 8202716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.
    Ferrandina G; Ranelletti FO; Martinelli E; Paglia A; Zannoni GF; Scambia G
    BMC Cancer; 2006 Jul; 6():182. PubMed ID: 16831230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
    Colombo N
    Future Oncol; 2013 Dec; 9(12 Suppl):19-23. PubMed ID: 24195526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
    Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
    BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.
    Siddiqui GK; Maclean AB; Elmasry K; Wong te Fong A; Morris RW; Rashid M; Begent RH; Boxer GM
    Angiogenesis; 2011 May; 14(2):155-61. PubMed ID: 21221762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
    Gadducci A; Brunetti I; Cosio S; Giannessi PG; Genazzani AR; Conte P
    Anticancer Res; 1997; 17(6D):4703-8. PubMed ID: 9494592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group.
    Stewart L;
    Cochrane Database Syst Rev; 2000; (2):CD001418. PubMed ID: 10796788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control.
    Petrillo M; Anchora LP; Scambia G; Fagotti A
    Oncologist; 2016 May; 21(5):532-4. PubMed ID: 27009941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOX18 expression predicts response to platinum-based chemotherapy in ovarian cancer.
    Pula B; Kobierzycki C; Solinski D; Olbromski M; Nowak-Markwitz E; Spaczynski M; Kedzia W; Zabel M; Dziegiel P
    Anticancer Res; 2014 Aug; 34(8):4029-37. PubMed ID: 25075026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?
    Cannistra SA
    J Clin Oncol; 2002 Mar; 20(5):1158-60. PubMed ID: 11870154
    [No Abstract]   [Full Text] [Related]  

  • 20. A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy.
    Zhang S; Yuan Y; Hao D
    PLoS One; 2014; 9(12):e113169. PubMed ID: 25437005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.